<DOC>
	<DOCNO>NCT01398085</DOCNO>
	<brief_summary>IoN phase II/ III trial look ascertain whether radio-iodine ablation necessary low risk differentiate thyroid cancer patient .</brief_summary>
	<brief_title>IoN- Is Ablative Radio-iodine Necessary Low Risk Differentiated Thyroid Cancer Patients</brief_title>
	<detailed_description>Phase II : determine recruitment phase III trial feasible , target 10 patient per month minimum 6 month ( evaluate within month 7-18 trial ) . Phase III : determine whether 5-year disease-free survival rate among patient routine Radioactive iodine ( RAI ) ablation non-inferior .</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<mesh_term>Cadexomer iodine</mesh_term>
	<criteria>R0 total thyroidectomy ( one two stage , residual disease present ; Rx discretion MDT ) within last 6 month Negative pregnancy test woman child bear potential Aged 16 WHO performance status 0 2 , selfcaring Histological confirmation differentiate thyroid carcinoma : MDT decision inclusion base overall clinicopathological assessment Papillary thyroid cancer Non aggressive histological feature ( small foci aggressive histology allow discretion MDT ) pT1a ( ) : individual focus ≤1cm pT1b pT1b ( ) : &gt; 12cm pT2 pT2 ( ) : &gt; 24cm pT3 pT3 ( ) : &gt; 4cm pT3 R0 : size minimal extrathyroidal extension recommend MDT pN0 pN1a pNX Encapsulated follicular variant papillary thyroid cancer ( EFVPTC ) capsular invasion Follicular thyroid cancer/ Hurthle cell cancer minimally invasive capsular invasion ( four focus possible invasion intra capsular vessel discretion MDT ) pT1b : &gt; 1 4 cm pT3 R0 : ( 4cm ) minimal extrathyroidal extension recommend MDT Histological material available Central Review Willing use contraception duration trial 6 month post radioiodine treatment ( female ) 4 month post treatment ( male ) , allocated ablation group . N.B . Multifocal tumour ( ≥2 focus ) histological type designate `` ( ) '' , size large focus determines classification ( describe TNM 7th edition ) . For example , two focus , one 0.8cm 3cm , classification base 3cm focus ; i.e . pT2 ( ) . pT1a Papillary Follicular carcinoma unifocal ≤1cm size &lt; 4cm Encapsulated Follicular Variant Papillary Thyroid Cancer ( EFVPTC ) capsular invasion Anaplastic medullary carcinoma R1/R2 Thyroidectomy Patients : pN1b M1 Aggressive Papillary thyroid cancer follow feature : Widely invasive Poorly differentiate Anaplastic Tall cell Columnar cell Diffuse sclerosing variant Follicular thyroid cancer/ Hürthle cell cancer follow feature : Anaplastic Widely invasive Poorly differentiate Tumours great 4cm Incomplete resection lobectomy pT4 macroscopic microscopic tumour invasion locoregional tissue structure Pregnant woman woman breast feeding Patients CT perform iv contrast le 23 month ablation Previous treatment thyroid cancer ( except surgery ) Previous malignancy limit life expectancy likely interfere patient 's ability able comply treatment and/or followup least 5 year Dysphagia , Oesophageal stricture , Active gastritis , Gastric erosion , Peptic ulcer , Suspected reduce gastrointestinal motility MDT decision ablation suitability trail light severe comorbid condition/s : Unstable angina Recent myocardial infarction cerebrovascular accident ( CVA ) Severe labile hypertension Any patient comply radiation protection include : patient learn difficulty patient dementia patient tracheostomy require nursing care patient require frequent nursing/ medical supervision</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Papillary thyroid carcinoma</keyword>
	<keyword>Follicular thyroid carcinoma</keyword>
	<keyword>Hurthle cell carcinoma thyroid</keyword>
	<keyword>Iodine Radioisotopes</keyword>
</DOC>